An analysis by scientists from the institution and the University of Erlangen-Nuremberg is presented in The Lancet Infectious Diseases.

Particularly in regions where BQ.1.1 is widespread, clinicians should not rely solely on antibody therapy when treating high-risk infected patients, but should also consider other drugs such as Paxlovid, study leader Markus Hoffmann said. In addition, new antibody therapies need to be developed.

weekly report

In its latest weekly report last Thursday, the Robert Koch Institute pointed to a fourfold increase in the number of new variants of the virus in Germany over the past four weeks. Thus, the proportion of the pathogen was eight percent.

In their cell culture laboratory studies, the researchers found that BQ.1.1 could not be neutralized by either single antibodies or antibody cocktails. Other subtypes were already immune to some drugs. According to him, the cause of resistance is mutations in the so-called spike protein of the corona virus.

Develop new treatments

“The ever-increasing development of the resistance of Sars-CoV-2 variants necessitates the development of new antibody therapies that are specifically tailored to currently and future circulating virus variants,” explained Stefan Pöhlmann, head of infection biology at the Primate Center. . “Ideally, they should target regions of the spike protein that have little potential for escaping mutations.”

© dpa-infocom, dpa:221123-99-633561/5
© dpa